SeaStar Medical announces receipt of Category B Coverage Letter from CMS

SeaStar Medical announces receipt of a Category B Coverage Letter from the U.S. Centers for Medicare & Medicaid Services, CMS, for the NEUTRALIZE-AKI pivotal trial evaluating the Company’s Selective Cytopheretic Device, SCD, in adults with acute kidney injury, AKI. CMS will pay for certain expenses incurred by medical centers treating patients covered by Medicare or Medicaid who are enrolled in the trial, which will cover a portion of SeaStar Medical’s trial-related costs. “We anticipate that CMS reimbursement will provide substantial overall cost savings for this trial while accelerating the activation of new sites, including several that have been waiting for this determination. With more trial sites activated we expect a meaningful acceleration in patient enrollment,” said Eric Schlorff, SeaStar Medical CEO.